On March 27, 2024, Shanghai Vitalgen Biomedical Co., Ltd. (hereinafter referred to as "Vitalgen") announced that it will participate in the 27th Annual Meeting of American Society of Gene & Cell Therapy (ASGCT) to be held in Baltimore from May 7 to May 11, 2024. During the meeting, Vitalgen will present nine of its latest R&D achievements covering gene therapies, gene editing technology platforms and product pipelines in the form of oral and poster presentations. As one of the key oral presentations, the Phase 1/2 clinical trial data of VGR-R01, a gene therapy independently developed by Vitalgen for the treatment of Bietti crystalline dystrophy (BCD), will be announced for the first time globally.
Dr. Zhao Xiaoping, CEO of Vitalgen, said: "It is a great honor for us to receive the invitation from ASGCT, the top academic conference in the field of gene therapy, to introduce three of our studies in the form of oral presentations at the annual meeting, and six of our study abstracts have also been accepted by ASGCT, which fully demonstrates the solid technology foundation and world-leading R&D capability of Vitalgen in the field of gene therapy. The excellent Phase 1/2 clinical trial data of VGR-R01, a globally innovative product indicated for the blinding retinal degenerative disease BCD, will be announced at this meeting. We are looking forward to presenting the promising clinical achievements of this potential "First-in-class" product and having in-depth academic discussion with all attendees. We will try our best to make our vision of 'May all diseases have a chance of curing' a reality, and make every effort to promote the clinical development and commercialization of our product pipelines, aiming to benefit the large population of patients with hereditary rare diseases and neurodegenerative diseases as soon as possible."
The oral presentations that Vitalgen will give at the 27th ASGCT Annual Meeting are listed as follows:
Serial number
|
Topic
|
Report theme
|
Report form
|
|
1
|
AAV gene therapy
|
Subretinal Gene Therapy in Patients withBietti Crystalline Dystrophy: Preliminary Resultsof a Phase 1/2 Clinical Trial
|
Oral presentation
|
|
2
|
AAV gene therapy
|
VGN-RO8b Gene Therapy forNeuronopathic Gaucher Disease
|
Oral presentation
|
|
3
|
Lipid nanoparticle technology platform
|
Development of a Novel “CLAMP” Platform for Scalable Preparation of Antibody-Conjugated Lipid Nanoparticles for T Cell-Targeted mRNA Delivery
|
Oral presentation
|
In addition, six study abstracts of Vitalgen will also be presented at this year's ASGCT in the form of poster presentations, covering the latest research progress in gene therapy, gene delivery and gene editing technology platforms in the fields of hematological and metabolic diseases, central nervous system diseases, etc.
